SAS Output

16-OCT-2019 6:10

LYMPH ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob 1 T 1 TGR-1202 + Obinutuzumab 150 12 10 6 4 1 0 01/23/2018 267 98
        2 Lenalidomide + Obinutuzumab   12 10 6 4 2 0      
        3 CHOP + Obinutuzumab   7 4 2 1 1 0      
        4 Bendamustine + Obinutuzumab   6 6 2 0 0 0      
            37 30 16 9 4 0      
 
  S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD 1 Y 1 Nivolumab + AVD 987 6 6 6 6 5 2 08/29/2019 153 60
        2 Brentuximab Vedotin + AVD   6 6 6 6 4 1      
            12 12 12 12 9 3      
 
Yes E4412-HD, RR, Ipilimumab +Nivo +Brentuximab Vedotin 1 E Total Registrations   4 4 4 0 0 0 04/17/2019 127 53
            4 4 4 0 0 0      
 
  EA4151-Lymph, AHCT +/-Ritux, MRD Neg 0 E Total Registrations   39 28 15 11 3 1 04/03/2018 161 72
            39 28 15 11 3 1      
 
    1 E Total Registrations   25 18 10 4 2 0 04/03/2018    
            25 18 10 4 2 0      
 

16-OCT-2019 6:10

LYMPH Recently Closed Studies Accrual Report

The REPORT Procedure

Detailed and/or summarized report

Table 1

OPEN Study Date
Closed
Reg. Arm Total
Regs
Regs
Last
30 Days
Regs
Last
7 Days
T S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob 15-Oct-19 1 1 TGR-1202 + Obinutuzumab 12 1 0
        2 Lenalidomide + Obinutuzumab 12 2 0
        3 CHOP + Obinutuzumab 7 1 0
        4 Bendamustine + Obinutuzumab 6 0 0